

## MRC Centre for Drug Safety Science Workshop Exploring the benefits–risks of nanomedicines

Venue: The Foresight Centre, University of Liverpool 7<sup>th</sup> October 2010

9.00 – 9.30	Coffee and Registration	
9.30 – 9.45	Welcome Address	Steve Rannard and Kevin Park
<b>Morning Session (chairs: TBA)</b>		
9.45 – 10.10	Overview of current technologies available for application to nanomedicine	Michael Juhnke, Novartis
10.10–10.30	Discussion	
10.30 – 11.00	Coffee break	
11.00 – 11.25	Disease specific application of nanomedicine: infectious diseases	Andrew Owen, Liverpool
11.25–11.45	Discussion	
11.45 – 12.10	Disease specific application of nanomedicine: cancer	Gert Storm, Utrecht
12.10–12.30	Discussion	
12.30 – 13.30	Lunch	
<b>Afternoon Session (chairs: TBA)</b>		
13.30 – 13.55	In vitro and in vivo models for assessing nano–specific risk–benefits	Vyvyan Howard, Ulster
13.55–14.15	Discussion	
14.15 – 14.40	Nanomedicine: priorities for industry	Heike Dinter–Heidorn, Solvay
14.40–15.00	Discussion	
15.00 – 15.25	Nanomedicine: a regulatory perspective	Henry Stemplewski, MHRA
15.25– 15.45	Discussion	
15.45 – 16.15	Coffee	
16.15 – 17.00	Discussion session: Identifying gaps in skills and knowledge	Chair: Steve Rannard
17.00	Closing remarks	